A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Greater Baltimore Medical Center, Baltimore

Franklin Square Hospital Center, Baltimore

Northern Virginia Pelvic Surgery Assoc., Annandale

Carilion Gyn/Onc, Roanoke

Carolinas Medical Center, Charlotte

Memorial Health Univ. Med. Ctr., Savannah

Integrated Community Oncology Network, Jacksonville

Florida Hospital, Orlando

Univ. of Alabama at Birmingham, Birmingham

Northwest Alabama Cancer Center, Muscle Shoals

Comprehensive Cancer Institute, Huntsville

University of Kentucky, Lexington

Ohio State University College of Medicaine, Columbus

Pelvic Surgery Assoc., Columbus

Indiana University, Indianapolis

St. Vincent Hospital, Indianapolis

Wayne State Univ. Barbara Ann Karmanos Cancer Inst., Detroit

University Of Chicago, Chicago

Carle Clinic Association, Urbana

Cancer Center of Kansas, Wichita

Oklahoma Univ. Medical Center, Oklahoma City

St. Luke's Mountain States Tumor Institute, Boise

North Idaho Cancer Center, Coeur d'Alene

Arizona Cancer Center, Tucson

Cedars-Sinai Medical Center, Los Angeles

University of California, Los Angeles, Los Angeles

Southern California Permanente Medical Group (Kaiser), San Diego

Sharp Healthcare, San Diego

Ventura County Hematology Oncology Specialists, Oxnard

Alta Bates Comp. Cancer Ctr, Berkeley

California Cancer Crae, Inc, Greenbrae

Sutter Cancer Center, Sacramento

Kaiser Permanente Northwest Division, Portland

Corvallis Clinic, Corvallis

Norwalk Medical Group, Norwalk

Hematology Oncology, P.C., Stamford

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston

Center for Cancer and Hematologic Disease, Cherry Hill

Cooper Health System, Voorhees Township

Womens and Infants Hospital, Providence